Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Accumulated Expenses for 4 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 72.12% to $14.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.8 million through Dec 2025, down 72.12% year-over-year, with the annual reading at $14.8 million for FY2025, 72.12% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $14.8 million at Phathom Pharmaceuticals, roughly flat from $14.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $53.2 million in Q4 2024, with the low at $83000.0 in Q2 2025.
  • Average Accumulated Expenses over 4 years is $8.6 million, with a median of $2.8 million recorded in 2022.
  • Peak annual rise in Accumulated Expenses hit 872.27% in 2025, while the deepest fall reached 95.76% in 2025.
  • Over 4 years, Accumulated Expenses stood at $3.1 million in 2022, then soared by 458.34% to $17.2 million in 2023, then surged by 209.54% to $53.2 million in 2024, then crashed by 72.12% to $14.8 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $14.8 million, $14.8 million, and $83000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.